India’s Sun Pharma Prepares $12 Billion Bid for US-Based Organon in…

Sarah J · 2026-04-10T17:02:48.000Z

India-based Sun Pharmaceutical Industries is preparing a potential $12 billion bid to acquire US-based Organon, marking what could become the largest overseas acquisition ever by an Indian pharmaceutical company. The move signals Sun Pharma’s ambition to significantly expand its global footprint, particularly in the women’s health and specialty medicines segment, where Organon has a strong portfolio. Spun off from Merck & Co., Organon focuses on biosimilars, established brands, and women’s health products, offering a complementary fit to Sun Pharma’s existing capabilities. If successful, the acquisition would provide Sun Pharma with immediate scale in regulated markets such as the United States and Europe, strengthening its position in high-value therapeutic segments. It would also enable the company to diversify its revenue streams and reduce dependence on generic drug markets, which are increasingly facing pricing pressures. The potential deal comes at a time when Indian pharmaceutical companies are actively pursuing global expansion through large-scale acquisitions, leveraging strong balance sheets and growing expertise in complex generics and specialty drugs. For Sun Pharma, this would mark a transformative step in its journey toward becoming a global innovation-led pharma leader. From a broader perspective, the deal reflects deepening India–US healthcare linkages and highlights the growing role of Indian companies in shaping the global pharmaceutical landscape. As cross-border consolidation accelerates, such transactions are expected to redefine competitive dynamics and drive innovation across the industry. If finalized, the Sun Pharma-Organon deal could set a new benchmark for outbound M&A from India, reinforcing the country’s emergence as a major force in global life sciences and healthcare innovation.

Member Login Get Access

India’s Sun Pharma Prepares $12 Billion Bid for US-Based Organon in… | SEINET